
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc. demonstrates a favorable outlook due to the promising efficacy signals of its lead program, TARA-002, which achieved a 100% high-grade complete response rate in BCG-unresponsive patients and maintained a notable durability rate of 67% at 12 months. Additionally, the program showed a high-grade complete response rate of 76% among BCG-naïve patients, suggesting significant potential for market adoption across both academic centers and community practices that prioritize long-term outcomes. The overall positive feedback from key opinion leaders (KOLs) indicates that TARA-002 could become a competitive treatment option in the evolving landscape of therapies for patients with limited treatment alternatives.
Bears say
Protara Therapeutics faces a challenging outlook as management anticipates a decline in the clinical response (CR) rates for its therapies, which could impact the company's market position despite highlighting the substantial unmet needs in the treatment landscape for lymphatic malformations. The expectation of reduced real-world CR rates, particularly in the BCG-unresponsive setting, raises concerns about the overall effectiveness and market adoption of TARA-002 and other therapies in its portfolio. Additionally, uncertainties surrounding the company's valuation and the risks associated with achieving positive outcomes further contribute to the negative sentiment regarding its stock performance.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares